Europe curtails use of cipro antibiotics
A committee for the European Medicines Agency (EMA) has recommended suspending entirely or restricting the use of fluoroquinolone and quinolone antibiotics because of the risk for "disabling and potentially permanent" adverse effects, the agency announced today.
The EMA Committee for Human Medicinal Products (CHMP) endorsed recommendations put forth in October by the agency's Pharmacovigilance Risk Assessment Committee (PRAC). The committee concluded that marketing authorization for medicines containing cinoxacin, flumequine, nalidixic acid, and pipemidic acid should be suspended.
The CHMP also confirmed that the use of the remaining fluoroquinolone antibiotics should be restricted.
Updated prescribing information for healthcare professionals and information for patients will describe the disabling and potentially permanent adverse effects and will advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of an adverse effect involving muscles, tendons or joints, and the nervous system, the EMA said.
A committee for the European Medicines Agency (EMA) has recommended suspending entirely or restricting the use of fluoroquinolone and quinolone antibiotics because of the risk for "disabling and potentially permanent" adverse effects, the agency announced today.
The EMA Committee for Human Medicinal Products (CHMP) endorsed recommendations put forth in October by the agency's Pharmacovigilance Risk Assessment Committee (PRAC). The committee concluded that marketing authorization for medicines containing cinoxacin, flumequine, nalidixic acid, and pipemidic acid should be suspended.
The CHMP also confirmed that the use of the remaining fluoroquinolone antibiotics should be restricted.
Updated prescribing information for healthcare professionals and information for patients will describe the disabling and potentially permanent adverse effects and will advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of an adverse effect involving muscles, tendons or joints, and the nervous system, the EMA said.
